X-linked Hypophosphatemia (XLH) Clinical Trial
— PRADEXOfficial title:
Prevention of Spontaneous Dental Abscesses in Children With X-linked Hypophosphatemia: a Multicentre Randomized Controlled Trial
This study is a prospective, randomized, single-blind, split-mouth, national multicenter trial, comparing the efficacy of a self-etch adhesive system combined (SAM) with a flowable composite to that of a fluoride varnish for the prevention of spontaneous dental abscesses in children with XLH. For each patient, according to randomization, one side of the oral cavity is treated with the experimental treatment (application of the adhesive system to healthy anterior and posterior temporary teeth, and application of the flowable composite to healthy posterior temporary teeth), and the other side with the active comparator (fluoride varnish). The application process for both treatments is similar and will be renewed every 6 months (visits at 6, 12, 18 and 24 months) systematically for the SAM and the varnish, and in case of partial or total loss of the composite.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | November 1, 2025 |
Est. primary completion date | January 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Months to 8 Years |
Eligibility | Inclusion Criteria: - X-linked hypophosphatemia diagnosed by the doctor specializing in the disease. - Patients with at least two healthy contralateral quadrants (right and left) at inclusion defined by the absence of symptomatic or asymptomatic spontaneous abscess, carious lesion and trauma (concussion, subluxation, dislocation, crack, fracture) on all teeth in the quadrant. Exclusion Criteria: - Antibiotic treatment within 15 days prior to inclusion - Patients with a mental disability, - Patients with cancer, heart disease, sickle cell anemia, pathological bruxism - Patients with contraindications to study treatments |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | presence of spontaneous dental abscesses | Spontaneous dental abscesses is defined at least one of the following criteria, in the absence of cavities or dental trauma:
- Clinical criterion: Clinical vestibular, lingual or palatal gingival abscess , or Fistulized abscess, or Fistula, or Head and neck cellulitis . - Radiological criteria: Pathological bone radiolucency (periapical or interradicular), visible on a retro-alveolar image. The occurrence of at least one spontaneous abscess (binary criterion) will be evaluated for each of the treated sites (4 quadrants per child, corresponding to 2 quadrants on each side of the oral cavity). Only abscesses occurring on a tooth with a history of abscess and free from abscess at inclusion will be considered. Abscesses occurring on a tooth with a carious lesion will not be considered. |
24 month after inclusion | |
Secondary | Correlation beween the occurrence of spontaneous abscesses and the age at which 1alpha-(OH)D3 was initiated | 24 month after inclusion | ||
Secondary | infectious complication | infectious complication is defined as :sepsis, cavernous sinus thrombophlebitis, mediastinitis, necrotizing fasciits, brain abscess, purulent melting of eye | 24 month after inclusion | |
Secondary | temporary teeh extracted following a spontaneous abscess on the teeth | 24 month after inclusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04842019 -
Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH
|
Phase 4 | |
Active, not recruiting |
NCT04842032 -
Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH
|
Phase 4 | |
Completed |
NCT04049877 -
Retrospective and Prospective Disease Progression and Quality of Life in XLH
|
||
Completed |
NCT04188964 -
Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age
|
Phase 1/Phase 2 |